MAP17 and SGLT1 Protein Expression Levels as Prognostic Markers for Cervical Tumor Patient Survival
Open Access
- 13 February 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (2), e56169
- https://doi.org/10.1371/journal.pone.0056169
Abstract
MAP17 is a membrane-associated protein that is overexpressed in human tumors. Because the expression of MAP17 increases reactive oxygen species (ROS) generation through SGLT1 in cancer cells, in the present work, we investigated whether MAP17 and/or SGLT1 might be markers for the activity of treatments involving oxidative stress, such as cisplatin or radiotherapy. First, we confirmed transcriptional alterations in genes involved in the oxidative stress induced by MAP17 expression in HeLa cervical tumor cells and found that Hela cells expressing MAP17 were more sensitive to therapies that induce ROS than were parental cells. Furthermore, MAP17 increased glucose uptake through SGLT receptors. We then analyzed MAP17 and SGLT1 expression levels in cervical tumors treated with cisplatin plus radiotherapy and correlated the expression levels with patient survival. MAP17 and SGLT1 were expressed in approximately 70% and 50% of cervical tumors of different types, respectively, but they were not expressed in adenoma tumors. Furthermore, there was a significant correlation between MAP17 and SGLT1 expression levels. High levels of either MAP17 or SGLT1 correlated with improved patient survival after treatment. However, the patients with high levels of both MAP17 and SGLT1 survived through the end of this study. Therefore, the combination of high MAP17 and SGLT1 levels is a marker for good prognosis in patients with cervical tumors after cisplatin plus radiotherapy treatment. These results also suggest that the use of MAP17 and SGLT1 markers may identify patients who are likely to exhibit a better response to treatments that boost oxidative stress in other cancer types.Keywords
This publication has 44 references indexed in Scilit:
- p38α limits the contribution of MAP17 to cancer progression in breast tumorsOncogene, 2012
- Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overviewJournal of Translational Medicine, 2011
- Coexpression of SGLT1 and EGFR is associated with tumor differentiation in oral squamous cell carcinomaOdontology, 2011
- Chemical Interrogation of FOXO3a Nuclear Translocation Identifies Potent and Selective Inhibitors of Phosphoinositide 3-KinasesPublished by Elsevier BV ,2009
- Reactive Oxygen Species, Cancer and Anti-Cancer TherapiesCurrent Chemical Biology, 2009
- MAP17 inhibits Myc-induced apoptosis through PI3K/AKT pathway activationCarcinogenesis: Integrative Cancer Research, 2007
- Large scale genetic screen identifies MAP17 as protein bypassing TNF-induced growth arrestJournal of Cellular Biochemistry, 2007
- MAP17 overexpression is a common characteristic of carcinomasCarcinogenesis: Integrative Cancer Research, 2007
- MAP17 enhances the malignant behavior of tumor cells through ROS increaseCarcinogenesis: Integrative Cancer Research, 2007
- Management of cervical cancerEuropean Journal of Surgical Oncology, 2006